CordenPharma in France Reports Successful FDA Inspection
PTSM: Pharmaceutical Technology Sourcing and Management
The CordenPharma Chenôve, France manufacturing facility completed an FDA Inspection with no 483s reported.
CordenPharma announced on Aug. 31, 2016 that the CordenPharma Chenôve (France) manufacturing facility completed an FDA Inspection and received a successful response with no 483s reported. The previous FDA Inspection took place in 2014.
Yves Michon, Managing Director of CordenPharma Chenôve comments, “We are pleased with the outcome of the FDA Inspection in August 2016, as it reflects our willingness to comply with the highest level of cGMP regulatory compliance while continuously improving our standards for our customers and their projects going forward.”
Source: CordenPharma
FDA Grants Full Approval for Symptomatic Tenosynovial Giant Cell Tumor Treatment
February 18th 2025Tenosynovial giant cell tumor (TGCT) is rare and non-malignant, forming in or near joints, but which if left untreated can cause damage to joints and surrounding tissue, potentially leading to significant disability.
